Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0923 ECP Libra
        BioCentury & Getty Images

Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

Libra aims at altered autophagy, neurotoxic protein production pathways shared across neurodegenerative disorders

Libra aims at altered autophagy and neurotoxic protein production pathways shared across neurodegenerative disorders starting with ALS.

Sep 24, 2020 | 12:56 AM GMT

Axxam spinout Libra is targeting autophagy and toxic protein production pathways common to multiple neurodegenerative disorders, starting with ALS.

Libra Therapeutics Inc.

Read the full 793 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE